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Structural evidence has demonstrated that P-glyco-
protein (P-gp) undergoes considerable conformational
changes during catalysis, and these alterations are im-
portant in drug interaction. Knowledge of which re-
gions in P-gp undergo conformational alterations will
provide vital information to elucidate the locations of
drug binding sites and the mechanism of coupling. A
number of investigations have implicated transmem-
brane segment six (TM6) in drug-P-gp interactions, and
a cysteine-scanning mutagenesis approach was directed
to this segment. Introduction of cysteine residues into
TM6 did not disturb basal or drug-stimulated ATPase
activity per se. Under basal conditions the hydrophobic
probe coumarin maleimide readily labeled all intro-
duced cysteine residues, whereas the hydrophilic fluo-
rescein maleimide only labeled residue Cys-343. The am-
phiphilic BODIPY-maleimide displayed a more complex
labeling profile. The extent of labeling with coumarin
maleimide did not vary during the catalytic cycle,
whereas fluorescein maleimide labeling of F343C was
lost after nucleotide binding or hydrolysis. BODIPY-ma-
leimide labeling was markedly altered during the cata-
lytic cycle and indicated that the adenosine 5-(,-
imino)triphosphate-bound and ADP/vanadate-trapped
intermediates were conformationally distinct. Our data
are reconciled with a recent atomic scale model of P-gp
and are consistent with a tilting of TM6 in response to
nucleotide binding and ATP hydrolysis.
The ubiquitously expressed P-glycoprotein (P-gp,1 ABCB1) is
a “multidrug” transporter capable of mediating the transloca-
tion of numerous chemically and functionally unrelated com-
pounds. The broad selectivity is based on the presence of mul-
tiple drug binding sites (1–4) that are localized within the
transmembrane domains (TMDs) (5, 6). P-gp is a primary ac-
tive transporter belonging to the ATP binding cassette family
(7), and ATP hydrolysis occurs in the two cytosolic nucleotide
binding domains (NBDs) (8), both of which are essential for
transport activity (9, 10). Active transport mechanisms require
(i) binding site re-orientation and (ii) binding site affinity
changes that are directly coupled to the provision of energy,
usually through ATP hydrolysis (11, 12). These fundamental
events in a transport cycle have been demonstrated for P-gp,
and the data have generated possible models outlining the
sequence of binding site changes driven by nucleotide binding
and hydrolysis (13, 14).
The mechanism of coupling the drug binding event to ATP
hydrolysis is, however, poorly understood for P-gp. Drug bind-
ing to the TMDs is known to stimulate ATP hydrolysis (15, 16)
and modulate the fluorescence characteristics of a probe at-
tached within the NBD (17), providing evidence for TMD 3
NBD communication. The reverse communication pathway has
also been observed (18), and numerous biophysical techniques
have demonstrated that P-gp undergoes tertiary structural
changes in response to both nucleotide binding and subsequent
hydrolysis (19, 20). Direct evidence that the TMDs undergo
functionally important conformational transitions has been ob-
tained from structural investigations using electron microscopy
of two-dimensional crystals (21, 22). However, this evidence
does not indicate which of the 12 transmembrane segments is
affected or which protein regions transduce the communication
between TMDs and NBDs.
Structural evidence has proposed that the TMD is organized
into a “ring” of protein surrounding a central aqueous pore (21,
22) similar to the arrangement of the TMDs observed in the
atomic resolution structures for the bacterial ABC transporters
BtuCD (23) and MsbA (24). Initial topographical maps using
cysteine-scanning mutagenesis rejected the symmetric and
mirror image arrangements of TM segments for P-gp in favor of
the “cyclone model” (25). However, a more recent manuscript
by the same authors has revised this model (26), reverting to
the initial suggestion of a ring of helices surrounding the aque-
ous central pore. Clearly, more work is required to elucidate
the precise configuration of TM segments in P-gp. A consistent
feature of such investigations has been that (i) TM segments 6
and 12 approach each other at the cytoplasmic membrane face
(25, 27, 28), and (ii) the TM segments 5, 6, 11, and 12 are in
close proximity (25, 29). Recently, an atomic scale model of
P-gp, based on the MsbA structure, has been proposed that
agrees with the two points taken from cross-linking data (30).
This model allows more focused site-directed mutagenesis in-
vestigations to fully elucidate the protein topography.
The earliest attempts to elucidate the drug binding site(s)
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labeled P-gp with photoactivable drugs and identification of
proteolytic fragments using specific antibodies (5, 6, 31, 32).
The labeled fragments comprised elements of TM helices 5, 6,
11, and 12, although many other species were observed. A
recent investigation using the more sophisticated mass spec-
troscopic approach identified similar structural elements (33).
However, it is worth noting that a major drawback with pho-
toactivable drugs is their inherent reactivity and, thus, may
label residues distant to the actual pharmacophoric region (34).
Investigations employing mutagenesis approaches identified
numerous residues throughout the TM segments of P-gp that
contribute to protein function (35–38). They were not confined
to a single TM segment; however, a significant proportion was
localized to TM6. Selection of cell lines in actinomycin D (39) or
doxorubicin with PSC833 (40) produced expression of P-gp with
mutations to different residues within TM6, and in both cases
the mutation led to an altered spectrum of resistance compared
with wild type protein. Site-directed mutagenesis also indi-
cated that residues Ser-337, Val-338, Ile-340, Gly-341, Ala-342,
Ser-344, and Gly-346 were involved in drug transport by P-gp.
Because most of these investigations use cellular drug resist-
ance profiles as the indicator for P-gp function. it is unclear
what aspect of the transport cycle was impaired (e.g. drug
binding or allosteric communication). These lines of circum-
stantial evidence clearly implicate TM6 as playing a defining
role in the overall transport mechanism. TM6 is directly linked
to the N-terminal NBD, and a role in communication may
be hypothesized.
The present investigation uses a cysteine-scanning mutagen-
esis approach combined with fluorescent labeling to elucidate
the topography of this key TM segment in P-gp. The protein
was then trapped in nucleotide-bound and post-hydrolytic con-
formations of the catalytic cycle to ascertain the nature of
conformational changes in TM6 produced by events in the
NBDs. The results were explained using the recently described
atomic model of P-gp.
EXPERIMENTAL PROCEDURES
Materials—BODIPY-maleimide, fluorescein-maleimide, and couma-
rin-maleimide were all purchased from Molecular Probes (Leiden, NL).
Octyl--D-glucoside and nickel nitrilotriacetic acid His Bind Superflow
resin were obtained from Merck. [3H]Phosphatidylcholine (83 Ci/mmol)
was purchased from Amersham Biosciences, and dimethyl sulfoxide
(Me2SO) disodium adenosine triphosphate (Na2ATP), cholesterol, vin-
blastine, nicardipine and sodium orthovanadate were all from Sigma.
Crude Escherichia coli lipid extract was obtained from Avanti Polar
Lipids (Alabaster, AL). Insect-Xpress medium was purchased from
Cambrex BioScience (Nottingham, UK), and Excell 405 was from AMS
Biotechnology (Abingdon, UK). All other reagents were of at least
analytical grade.
Production of Recombinant Baculovirus—Expression and character-
ization of a cysteine-less, histidine-tagged P-gp in mammalian cells has
been described (41, 42). Single cysteines were introduced into the cys-
teine-less multidrug resistance (MDR1)-coding sequence by site-di-
rected mutagenesis as described previously (41). The following muta-
genic oligonucleotides were used (5 to 3; in each case the cysteine
codon is in bold): oligoV331C, TCTATTGGACAATGCCTCACTGTA; oli-
goT333C, ATTGGACAAGTTCTCTGCGTATTCTTTTC; oligoF335C,
CTCACTGTATGCTTTTCTGTGTTAATTGGG; oligoS337C, CTGTATT-
CTTTTGTGTGTTAATTGGG; oligoL339C, CTTTTCTGTATGCATTG-
GGGCT; oligoG341C, CTGTATTAATTTGCGCATTTAGTGTTGG; olig-
oF343C, TTTTCTGTATTGATTGGGGCTTGTAGTGTTGG.
Additionally, all oligonucleotides were designed to generate a restric-
tion site, which is silent with respect to the coding sequence. This was
done to monitor subsequent cloning steps by restriction digest profiles
(italicized if outside the cysteine codon). The nucleotide sequences of the
mutated DNA fragments were verified by DNA sequencing. The entire
coding sequence for cysteine-less-P-gp and single cysteine mutants,
including the 5 Kozak sequence, was introduced into the baculoviral
transfer vector pBacPAK9 (Clontech), and recombinant baculoviruses
were generated by in vivo recombination with BacPAK6 DNA
(Clontech).
Expression of P-gp and Isolation of Insect Cell Membranes—The
Trichoplusia ni (High Five) cell line was routinely used for the expres-
sion of P-gp and maintained in shaking suspension cultures as previ-
ously described (42). High Five cells at a density of 3.106 cells/ml were
infected with recombinant baculovirus (5.107 plaque-forming units/
ml) at a multiplicity of infection of 5. After 2 h of incubation with virus,
the cells were diluted to a density of 1.5  106 cells/ml and grown for a
further 3 days before harvesting by centrifugation (2000  g for 10
min). Crude membrane preparations were isolated as previously de-
scribed (42), and the final membrane preparations were stored in high
sucrose buffer at 80 °C for up to 6 months before further use.
Purification and Reconstitution of P-gp—Membrane preparations
were solubilized in buffer containing 2% (w/v) octyl--D-glucoside and
P-gp-purified using nickel nitrilotriacetic acid by virtue of the C-termi-
nal hexahistidine tag. Reconstitution of the purified protein was
achieved by selective detergent adsorption, and efficiency was moni-
tored by comparing lipid and protein migration after sucrose density
gradient ultracentrifugation. Full details of the purification and recon-
stitution procedures have been described previously (42, 43).
Determination of Protein Concentration—Commercial protein assay
kits could not be used to quantify P-gp concentrations due to unaccept-
able levels of interference due to the presence of lipids, imidazole, and
glycerol. Consequently, a densitometric analysis of Coomassie-stained
SDS-PAGE gels was used. The P-gp bands were compared with a series
of known amounts of bovine serum albumin (0.2–1.0 g) on the same
gel. Gels were stained with 0.25% (w/v) Coomassie Blue (1–2 h) in 50%
(v/v) methanol and 10% (v/v) acetic acid. Destaining was achieved using
5% (v/v) methanol in 10% (v/v) acetic acid. The intensity of protein
bands was determined by quantitative densitometry using the NIH
Image Software.
Measurement of ATP Hydrolysis—ATP hydrolysis was determined by
measurement of inorganic phosphate liberation using a colorimetric
assay (44) with previously described modifications (42). Reconstituted
protein (0.3 g) was incubated at 37 °C for 20 min with varying con-
centrations of Na2ATP (0–1.75 mM). To determine the drug-stimulated
ATPase activity, samples were incubated with 30 M nicardipine. The
ATPase activity (nmol of Pi released/min/mg of P-gp) was plotted as a
function of ATP concentration, and the maximal velocity (Vmax) and
substrate affinity (KmATP) were determined by non-linear regression of
the Michaelis-Menten equation.
Where information on the effects of drugs on P-gp activity was
required, the ATPase activity was measured as above except at a
constant ATP concentration of 2 mM. The drugs (nicardipine and vin-
blastine) were added from stocks in Me2SO to provide a range between
109 and 104 M. The ATPase activity was plotted as a function of drug
concentration, and the potency of effect (EC50 or IC50) was derived from
non-linear regression of the general dose-response equation,
V  Vmin 
Vmax Vmin
1 10log EC50L
(Eq. 1)
where V is the rate of ATP hydrolysis, Vmin is minimal activity, Vmax is
maximal activity, and [L] is drug concentration.
Octanol:Water Partition Coefficient—The polarities of the three flu-
orescent probes, coumarin-maleimide (CM), fluorescein-maleimide
(FM), and BODIPY-maleimide (BM) were determined by assessment of
relative partitioning between aqueous and octanol solutions. Fluoro-
phores were added to 1 ml of buffer (20 mM Tris-HCl, pH 6.8) in a
concentration range of 3–100 M. Octanol (1 ml) was added, and the
solutions were mixed by rotation for at least 12 h at 20 °C to reach
partition equilibrium. After phase separation, absorption spectra were
recorded (Hitachi U-1200 spectrophotometer), and the maximal absorb-
ance was determined according to Beer’s Law. The extinction coeffi-
cients were: FM 	 83,000 cm1 M1, CM 	 33,000 cm1 M1, and BM 	
88,000 cm1 M1 as provided by the manufacturer (Molecular Probes,
Leiden NL). The ratio of the amount in the octanol compared with the
aqueous phase was calculated (P). The logarithm10 of this ratio (log P)
indicates the relative polarity.
Time Courses for Labeling of Single Cysteine-containing P-gp Iso-
forms—The time courses for reaction of maleimide-containing probes
with single cysteine mutant P-gp isoforms were undertaken to enable
determination of both the extent of labeling and the half-life describing
the reaction. Purified, reconstituted P-gp (1.5–3 g) was incubated at
20 °C with fluorescent probes (10 M) for 0, 10, 20, 30, 60, 120, 180, and
300 min. These conditions provided at least a 100-fold molar excess of
probe to P-gp to ensure that ligand depletion did not occur. Probes were
added from concentrated stocks in Me2SO, and the final solvent con-
centration did not exceed 0.5% (v/v). Reaction with probe was termi-
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nated by the addition of excess dithiothreitol (100 M), and the samples
were immediately placed on ice. Samples were diluted 1:1 in buffer (20
mM Tris-HCl, pH 7.4, 150 mM NH4Cl, 5 mM MgSO4, 0.02% NaN3) to
reduce the glycerol content and subjected to ultracentrifugation
(125,000  g, 15 min, 4 °C). The resulting pellets were resuspended in
Laemmli sample buffer, and proteins were resolved with 6% SDS-
PAGE. To trap P-gp in the nucleotide-bound state the samples were
preincubated in the presence of AMP-PNP (2 mM) for 20 min before the
addition of fluorophore (13). Vanadate trapping was achieved by prein-
cubation of the protein with 2 mM ATP and 300 M sodium orthovana-
date at 37 °C for 30 min before probe addition (13).
A further sample of denatured P-gp (i.e. fully accessible cysteine
residues) was included in each assay to determine the signal produced
by 100% labeling. The sample was subjected to ultracentrifugation as
described above and resuspended in 2% (w/v) SDS to denature the
protein and then incubated in the presence of probe (10 M) for a further
3 h.
Analysis of P-gp Labeling with Cysteine-reactive Fluorescent
Probes—Gels from the labeling reactions described above were ana-
lyzed using the BioDocIt Imaging system (UVP), which comprised a UV
light source ( 	 302 nm) and a CCD camera. Images of the gels were
quantified using densitometric analysis (NIH Image Software). Fluo-
rescence intensity of the P-gp bands were expressed as a percentage of
the denatured sample and plotted as a function of labeling time. The
profiles were fitted using non-linear regression of the exponential as-
sociation curve,
L  Lmax  1 ekt (Eq. 2)
where L is the percent labeled, Lmax is the maximum percent labeled, t
is time (min), and k is the observed rate constant for labeling.
The labeling rate constant may be converted to a half-life by the
relationship t1⁄2 	 Ln2/k. After imaging, the gels were stained with
Coomassie Blue for 30 min as described above to ensure equivalent
protein loading.
Data Analysis—All non-linear regression analyses were produced
using the GraphPad Prism3.0 program. A minimum data set was ob-
tained from at least three independent protein purification prepara-
tions, and all values are given as the mean 
 S.E. Multiple data
comparisons (3 sets) were analyzed using ANOVA with a Newman-
Keul post-hoc test, and statistical significance was presumed where
p  0.05.
RESULTS
Introduction of Single Cysteines into TM6 of P-gp Has Little
Effect on the ATPase Activity—Expression levels for the various
P-gp isoforms were similar (data not shown), and the yield of
purified protein from 50 mg of crude membrane was in the
range 41 
 4 g (S337C) to 65 
 9 g (Cys-less). Only the
F335C isoform was consistently outside this range (p  0.05,
n  10) and exhibited a yield of 28 
 6 g of P-gp. Reconstitu-
tion efficiencies were typically 95% of the protein co-migrating
through sucrose gradients with 80% of the total lipid. Those
samples where less than 70% of the protein co-migrated with
less than 70% of total lipid displayed low ATPase activity and
were excluded from further analysis.
The basal ATPase activity of Cys-less P-gp displayed a max-
imal activity (Vmax) of 0.58 
 0.15 mol of Pi min
1 mg1
characterized by an ATP affinity (Km) of 0.58 
 0.06 mM (Table
I). In the presence of the non-transported P-gp modu-
lator nicardipine, the activity was stimulated 2.9 
 0.3-fold to
a Vmax 	 1.46 mol of Pi min
1 mg1. In contrast, the Km for
ATP was only marginally reduced to 0.38 
 0.04 mM. The
maximal unstimulated ATPase activities of the mutant P-gp
isoforms containing a single cysteine in TM6 were in the range
0.35–0.65 mol of Pi min
1 mg1, none of which was signifi-
cantly different to that observed for Cys-less protein (Table I).
Similarly, the Km values (0.40–0.53 mM) did not differ statis-
tically between the TM6 mutant isoforms, indicating that the
catalytic cycle remained intact. Despite the introduction of
mutations at positions throughout TM6, both the maximal
ATPase activity (1.12–1.67 mol of Pi min
1 mg1) and the
degree of stimulation (2.2–3.5-fold basal) in the presence of
nicardipine were not statistically different from the values
observed for Cys-less P-gp (Table I). This indicates that the
communication from the nicardipine binding site to the NBDs
was unaffected by any of the changes introduced into TM6.
The effect of nicardipine on Vmax and Km was measured at a
high concentration (30 M) and may, therefore, mask subtle
changes in potency caused by mutation of TM6 residues to
cysteine. However, as shown in Table II, the potency for nicar-
dipine to stimulate ATP hydrolysis did not vary significantly
between the various isoforms (EC50 	 2.1–3.9 M). This con-
firms that the nicardipine-P-gp interaction is unaffected by the
mutations introduced into TM6. It has been previously demon-
strated that P-gp contains at least four distinct drug binding
sites (4) within the TMD. To examine the possibility that the
introduced mutations generate differential effects on the drug
binding sites, the interaction between vinblastine and P-gp was
also characterized. Neither the degree to which ATP hydrolysis
was stimulated by vinblastine (2.1–2.4-fold basal) nor the po-
tency to stimulate ATPase activity (EC50 	 4.0–7.2 M) for the
TM6 mutations varied significantly. The results demonstrate
that mutations introduced into TM6 did not alter the commu-
nication between the nicardipine and vinblastine binding sites
with the NBDs. Moreover, they suggest that the binding event
itself was unaffected.
Considerations for Labeling of Engineered Cysteine Resi-
dues—The introduction of cysteine residues at specific posi-
tions within TM6 produced P-gp isoforms essentially identical
to the Cys-less template. Therefore, the relative abilities of the
residues to react with three fluorescent probes displaying dis-
tinct physicochemical properties was employed as a means of
“topographical mapping” for TM6. The probes used were FM,
CM, and BM, which are shown in Fig. 1a and are known to
TABLE I
Characteristics of basal and drug-stimulated ATPase activity for purified reconstituted single cysteine mutants of P-gp
Pure, reconstituted P-gp (0.3 g) was incubated in the presence of varying ATP concentrations (0–1.75 mM), and the ATPase activity was
determined by measurement of inorganic phosphate liberation. Basal activity was measured in the absence of any drugs, whereas stimulated
activity was determined in the presence of 30 M nicardipine. The substrate affinity (Km) and maximal activity (Vmax) were determined by
non-linear regression of the Michaelis-Menten equation. -Fold stimulation was determined by the ratio of Vmax (stimulated)/Vmax (basal). Values
refer to the mean 
 S.E. obtained from at least eight independent protein purification preparations.
P-gp isoform
Substrate affinity , Km Maximal activity, Vmax -Fold
stimulationBasal Stimulated Basal Stimulated
mM mol Pi min
1 mg protein1
Cys-less 0.58 
 0.06 0.38 
 0.04 0.58 
 0.15 1.46 
 0.30 2.9 
 0.3
V331C 0.50 
 0.06 0.26 
 0.02 0.45 
 0.05 1.54 
 0.20 3.5 
 0.3
T333C 0.49 
 0.05 0.23 
 0.02 0.35 
 0.04 1.22 
 0.15 3.3 
 0.1
F335C 0.40 
 0.05 0.24 
 0.03 0.65 
 0.15 1.61 
 0.31 2.2 
 0.2
S337C 0.53 
 0.06 0.26 
 0.04 0.59 
 0.10 1.67 
 0.23 3.2 
 0.4
L339C 0.51 
 0.07 0.31 
 0.04 0.57 
 0.07 1.47 
 0.15 2.9 
 0.3
G341C 0.40 
 0.04 0.24 
 0.02 0.42 
 0.03 1.12 
 0.09 3.1 
 0.5
F343C 0.41 
 0.04 0.26 
 0.03 0.47 
 0.04 1.17 
 0.15 2.6 
 0.3
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generate stable covalent bonds with thiol groups under physi-
ological conditions. FM readily partitioned into the aqueous
phase, with only 3% of the compound found in octanol (i.e. log
P 	 1.7 
 0.2, n 	 3). In contrast, CM and BM were consid-
erably more hydrophobic, with partition extents of 95% (log P	
1.41 
 0.1, n 	 3) and 93% (log P 	 1.1 
 0.1, n 	 3),
respectively. Molecular modeling (DS Viewer Pro) indicated
that although the probes have similar molecular volumes
(FM 	 287 Å3, CM 	 293 Å3, BM 	 291 Å3), their topographies
were markedly distinct. FM has a charged carboxyl group,
thereby generating a hydrophilic face. CM has no charge, is
relatively compact, and due to its hydrophobicity will likely
partition into the bilayer in a random fashion. BM is bulky
overall, has a delocalized positive charge, and is therefore
likely to partition into the bilayer in a more ordered orientation
compared with CM.
Because of the difficulty in removing unbound probes, a
conventional fluorescence spectrophotometric assay could not
be used to measure probe attachment to the single cysteine
isoforms. The high partition coefficients of BM and CM ren-
dered dialysis, ultrafiltration, and ultracentrifugation largely
ineffective. Consequently a fluorescent SDS-PAGE method was
adopted to separate labeled protein from unbound probe and
enable quantitative analysis. Care was exercised to ensure that
(i) band fluorescent intensities were within the linear range
and (ii) that minor contaminating, cysteine-rich proteins do not
interfere with analyses. Typical time courses for labeling of
T333C with FM and G341C with CM are shown in Fig 1, b and
c, respectively. Panel b shows a time-dependent increase in the
labeling of T333C P-gp (lanes i–vii). Lane viii was loaded with
half the amount of protein in lanes i–vii. The protein sample in
lane viii had been denatured and, thus, provides a measure of
50% maximal attainable labeling. Quantification of lanes i–vii
by comparison with lane viii shows that the level of labeling
intensity was minimal (i.e. 6% at 300 min). All time courses for
labeling with probes were normalized to denatured protein
using this comparative approach. Panel c clearly demonstrates
that the labeling of G341C reached significantly higher levels
(lanes i-vii) when compared with denatured protein (lane viii),
which in this case indicates 100% labeling.
Extents and Rates of Labeling of Residues in TM6 under
Basal Conditions—Time courses similar to those shown in Fig.
1 were undertaken for all mutant P-gp isoforms and fitted with
the exponential association equation to generate a maximal
labeling intensity and the rate of this labeling reaction. Mutant
G324C, which contains a cysteine in an accessible extracellular
loop, was used as a positive control for labeling. Cys-less P-gp
was used as a negative control, and labeling to specific isoforms
was only deemed significant if it was significantly different to
residual labeling observed for Cys-less protein. Figs. 2a, 3a,
and 4a show the maximal extent of labeling obtained with the
three probes to each isoform. Nonspecific labeling of Cys-less
P-gp by FM was 4 
 1% (Fig. 2a), whereas G324C labeled to
100% with a half-life of 12 
 1 min (data not shown). Isoforms
V331C, T333C, F335C, S337C, L339C, and G341C displayed
labeling extents in the range 7–12%, and none was signifi-
cantly different from the Cys-less isoform (ANOVA). In con-
trast, F343C in the native protein conformation was accessible
to labeling with FM as adjudged by the 81 
 2% labeling extent
(Lext), which was characterized by a half-life (t1⁄2 	 47 
 8 min)
almost 4 times slower than observed for G324C. The data
suggest that of the seven mutated residues in TM6, only Cys-
343 was accessible to the hydrophilic probe FM.
The accessibilities of mutated TM6 residues to the hydropho-
bic probe CM (Fig. 3a) were considerably different to those
obtained with FM. The level of nonspecific interaction with the
Cys-less P-gp was higher (Lext 	 25 
 4%), and G324C was also
labeled by CM (Lext 	 102 
 4%), although the half-life (t1⁄2 	
31 
 4 min) was almost 3 times slower than observed for FM.
Each of the TM6 isoforms was fully labeled with CM as dem-
onstrated by Lext values in the range 87–107% (Fig. 3a), with
similar half-lives in the range 35–52 min. Only the L339C
isoform was significantly different with more rapid reaction
kinetics (t1⁄2 	 23 
 1 min, p  0.05, n 	 3).
Labeling of mutant TM6 isoforms with BM generated a pro-
file intermediate between those obtained with CM and FM
(Fig. 4a), perhaps reflective of its distinct physicochemical
properties. Nonspecific interaction with Cys-less protein was
19 
 1% and G324C labeled fully (Lext 	 97 
 3%) with a
half-life approximately double (t1⁄2 	 23 
 2 min) that obtained
for FM. Isoforms T333C, F335C, S337C, and G341C did not
label with BM since the Lext values (19–27%) were not signif-
TABLE II
Potency of drugs that affect the ATPase activity of purified
reconstituted single cysteine mutants of P-gp
Pure, reconstituted P-gp (0.3 g) was incubated in the presence of
ATP (2 mM) and varying concentrations of nicardipine, vinblastine, or
vanadate. Hydrolysis of nucleotide was detected by the liberation of
inorganic phosphate using a colorimetric assay. The potencies to stim-
ulate (EC50) or inhibit (IC50) activity were derived from non-linear
regression of the general dose-response relationship. Values refer to the
mean 
 S.E. obtained from a minimum of three independent protein
purification preparations.
P-gp isoform
Potency of drug effect
Nicardipine,
EC50
Vinblastine,
EC50
Vanadate,
IC50
M M M
Cys-less 3.2 
 0.3 4.2 
 0.6 4.0 
 0.4
V331C 3.3 
 0.4 7.2 
 1.7 3.2 
 0.4
T333C 2.3 
 0.2 4.6 
 0.4 3.9 
 0.8
F335C 2.3 
 0.4 4.2 
 0.8 5.5 
 1.1
S337C 2.7 
 0.5 4.1 
 1.0 5.8 
 0.8
L339C 2.1 
 0.3 5.1 
 0.8 4.2 
 0.7
G341C 3.9 
 0.5 4.0 
 0.6 6.8 
 1.3
F343C 2.1 
 0.3 5.6 
 2.7 2.7 
 0.8
FIG. 1. Labeling of single cysteine isoforms of P-gp with fluo-
rescent maleimide reagents. Structures of maleimide-containing
probes (a) and the fluorescence profiles of SDS-PAGE gels obtained for
time courses of fluorescein maleimide labeling of T333C (b) and couma-
rin maleimide labeling of G341C (c). Lanes i-vii refer to 10, 20, 30, 60,
120, 180, and 300 min of labeling. Lane viii demonstrates the fluores-
cence obtained in denatured P-gp isoforms. The amount of denatured
sample loaded in gel (panel b) was equivalent to half that in the native
samples and, therefore, refers to 50% of maximal labeling. In gel (panel
c) the amount of denatured sample loaded was equivalent to native
samples.
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FIG. 2. Extents of labeling mutant P-gp isoforms with fluores-
cein maleimide at different stages of the catalytic cycle. Purified,
reconstituted P-gp (1.5–3 g) was labeled with fluorescein maleimide
(10 M) for 0–300 min. Labeling was determined by fluorescent imaging
of SDS-PAGE gels and quantified with densitometry. The extent of
labeling (i.e. % labeling) was expressed as a percentage of that obtained
with denatured sample. Data were fitted with the exponential associa-
tion curve using non-linear regression. Cys-less represents the cysteine-
free mutant isoform. Labeling was undertaken for protein in the basal
(a), AMP-PNP-bound (b), or ADP/vanadate-trapped (c) states of P-gp.
The asterisk (*) indicates that labeling was significantly greater than
the nonspecific fluorescence obtained with Cys-less P-gp (p  0.01,
ANOVA with Newman Kuel post hoc test).
FIG. 3. Extents of labeling mutant P-gp isoforms with couma-
rin maleimide at different stages of the catalytic cycle. Purified,
reconstituted P-gp (1.5–3 g) was labeled with coumarin maleimide (10
M) for 0–300 min. Labeling was determined by fluorescent imaging of
SDS-PAGE gels and quantified with densitometry. The extent of label-
ing (i.e. % labeling) was expressed as a percentage of that obtained with
denatured sample. Data were fitted with the exponential association
curve using non-linear regression. Cys-less represents the cysteine-free
mutant isoform. Labeling was undertaken for protein in the basal (a),
AMP-PNP-bound (b), or ADP/vanadate-trapped (c) states of P-gp. The
asterisk (*) indicates that labeling was significantly greater than the
nonspecific fluorescence obtained with Cys-less P-gp (p  0.01, ANOVA
with Newman Kuel post hoc test).
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icantly different from those observed with Cys-less P-gp. The
V331C isoform was labeled with BM (Lext 	 62 
 4%), although
the half-life for this labeling was considerably slower (t1⁄2 	
143 
 21 min, p  0.05) than obtained for any other reaction.
L339C was also efficiently labeled with BM (Lext 	 71 
 2%);
however, the reaction kinetics were faster (t1⁄2 	 49 
 7 min)
than observed with V331C. Surprisingly, mutant F343C, which
was the only isoform labeled by the hydrophilic compound FM,
reacted with the amphiphilic probe BM (Lext 	 68 
 11%) with
a half-life of only 18 
 4 min.
Alterations in Labeling during the Catalytic Cycle—As dis-
cussed earlier, the ATP catalytic cycle is capable of inducing
large conformational changes in the TMDs of P-gp. To deter-
mine whether TM6 is influenced by this stimulus, the accessi-
bility of residues was determined in protein trapped at various
stages of the catalytic cycle. AMP-PNP binding and vanadate
trapping of P-gp were used to mimic the pre- and post-hydro-
lytic conformations (45). The maximal extents of labeling ob-
tained from full time-course data are shown for each isoform to
each probe in the presence of AMP-PNP (Fig. 2b, 3b, and 4b) or
after vanadate trapping (Fig. 2c, 3c, and 4c). Isoform F343C
was the only protein to label with the hydrophilic probe FM,
and the labeling was significantly reduced by both AMP-PNP
binding (Lext 	 29 
 3%) and vanadate trapping (Lext 	 26 

4%). Despite the reduced extent of labeling, the values re-
mained significantly different (p  0.05) from those obtained
with Cys-less P-gp (Lext 	 4
 1%). The residual labeled protein
is likely to arise from the proportion of F343C P-gp that was not
completely bound with AMP-PNP or vanadate-trapped. This
was confirmed by similar labeling half-lives compared with
nucleotide free F343C P-gp. F343C was the only isoform whose
labeling with FM was affected by the catalytic cycle because all
other mutant P-gp proteins remained inaccessible to labeling
with this hydrophilic molecule.
AMP-PNP binding did not significantly affect the labeling of
mutant TM6 isoforms by CM as evident by the Lext values in
the range 83–107% (Fig. 3b). Similarly, the kinetics of the
reaction were also unchanged (t1⁄2 values of 45–65 min) with the
exception of isoform L339C. This protein was the most rapidly
labeled with CM in the basal state (t1⁄2 	 21 
 1 min), and after
AMP-PNP binding the half-life was increased to 45 
 2 min.
However, the most dramatic effects on CM labeling were ob-
served in the vanadate-trapped protein. The extents of labeling
remained similar, with all residues displaying high accessibil-
ity (Lext  85%) as shown in Fig. 3c. However the half-lives
describing the labeling reaction were altered. Isoforms T333C
(t1⁄2 	 16 
 3 min) and F343C (t1⁄2 	 18 
 5 min) labeled with
CM with significantly increased rates compared with the val-
ues observed in either basal conditions or in the presence of
AMP-PNP, reflecting an increased accessibility of the intro-
duced cysteine residues. In the vanadate-trapped state, L339C
labeling (t1⁄2 	 28 
 3 min) regained the rapid reaction kinetics
with CM that were observed in the basal state but lost in the
nucleotide-bound protein.
The extent to which the amphiphilic probe BM labeled the
mutant P-gp isoforms Cys-331 and Cys-339 was greatly re-
duced in the AMP-PNP-bound state. Whereas under basal con-
ditions V331C, L339C, and F343C were accessible to BM, only
the latter was labeled (Lext 	 90 
 8%) after AMP-PNP binding
to the protein (Fig. 4b). This reflects a general reduction in the
overall residue accessibility after AMP-PNP binding at posi-
tions other than Cys-343. This was further confirmed by the
observation that the half-life of labeling with BM in F343C was
unaffected by the binding of AMP-PNP (t1⁄2 	 18 
 1 min)
compared with the basal state. Vanadate trapping of the F343C
isoform also failed to alter either the extent (Lext 	 98 
 3%) or
FIG. 4. Extents of labeling mutant P-gp isoforms with BODIPY-
maleimide at different stages of the catalytic cycle. Purified,
reconstituted P-gp (1.5–3 g) was labeled with BODIPY-maleimide (10
M) for 0–300 min. Labeling was determined by fluorescent imaging of
SDS-PAGE gels and quantified with densitometry. The extent of label-
ing (i.e. % labeling) was expressed as a percentage of that obtained with
denatured sample. Data were fitted with the exponential association
curve using non-linear regression. Cys-less represents the cysteine-free
mutant isoform. Labeling was undertaken for protein in the basal (a),
AMP-PNP-bound (b), or ADP/vanadate-trapped (c) states of P-gp. The
asterisk (*) indicates that labeling was significantly greater than the
nonspecific fluorescence obtained with Cys-less P-gp (p  0.01, ANOVA
with Newman Kuel post hoc test).
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half-life (t1⁄2 	 14 
 3 min) of labeling with BM (Fig. 4c). Thus,
in the basal state this residue is accessible to the hydrophilic
probe, and after progression through the catalytic cycle its
labeling “switches” to a preference for more hydrophobic
probes.
Isoform T333C, which was inaccessible to BM under basal
conditions, remained so after nucleotide binding and only
labeled to a significant extent in the vanadate-trapped state
(Lext 	 85 
 2%). In contrast, V331C was affected in the
opposite manner with accessibility only apparent in the basal
state. Residue Cys-337 only produced a significant level of
labeling (Lext 	 64 
 13%) when trapped in a post-hydrolytic
state with ADP and vanadate (Fig. 4c). The effects on L339C
accessibility to BM paralleled the observations with CM. La-
beling with BM was observed in the basal state (Lext 	 71 

2%), lost in the nucleotide-bound state, and then recovered
after ATP hydrolysis (Lext 	 62 
 12%). Two isoforms, F335C
and G341C, could not be labeled by BM under any conditions
and presumably lie in a region with low accessibility due to
proximity of other structural elements.
Overall, the results suggest that binding of AMP-PNP pro-
duces a conformational transition that decreases the accessi-
bility of a substantial proportion of TM6 and reduces access to
the aqueous environment. The subsequent hydrolytic step
leads to formation of a third transition state that despite in-
creases in accessibility of several TM6 residues to amphiphilic
probes appears not to allow the introduced cysteines exposure
to the aqueous environment.
DISCUSSION
TM6 has been widely implicated in mediating a key role in
drug transport by P-gp, although the exact molecular path-
way(s) or mechanism remains unknown. If TM6 is important
then it is likely to be involved in the bi-directional communi-
cation between the TMDs and NBDs of P-gp that is essential
for a coupled transport process. The present investigation sup-
ports this hypothesis by demonstrating that the topography of
TM6 undergoes significant reconfiguration between the nucle-
otide-free, the nucleotide-bound, and post-hydrolytic states of
P-gp. The topographical information and its nucleotide-driven
changes have been related to an atomic scale molecular model
recently presented for the nucleotide free state of P-gp (30).
Fig. 5a provides the relative arrangements of the 12 TM
segments in P-gp under basal conditions based on the model for
FIG. 5. Proposed arrangements of transmembrane segments of P-gp at various stages of the catalytic cycle. a, relative arrangements
of transmembrane segments of P-gp based on the proposed atomic scale homology model (30). The NBDs and connecting loops have been removed,
and the TM6 backbone is shown in yellow, whereas residues mutated to cysteine are also shown. The upper panel depicts the view from the
extracellular face, and the lower panel shows a “side-on” view. b, TM6 has been tilted with respect to the long axis to describe the accessibility
changes produced after the binding of AMP-PNP. c, TM6 has been tilted further to describe the accessibility changes produced after the transition
from AMP-PNP-bound (pre-hydrolytic) to the ADP/vanadate-trapped (post-hydrolytic) (Vi) states.
Topography of TM6 in P-glycoprotein 34919
 at A
STO
N
 U
N
IV
ERSITY
 on M
ay 2, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
nucleotide-free P-gp and excludes connecting loops and NBDs
for clarity (30). The relative arrangement of TMs 5, 6, 11, and
12 around a central pore within the model agrees with the
majority of available cross-linking data for P-gp (25, 26, 46).
The side view of the region near TM6 indicates that a large
number of the residues mutated appear to face the lipid envi-
ronment, which accounts for the ease of labeling obtained with
CM throughout. The low accessibility of residues Cys-333, Cys-
337, and Cys-341 to labeling with BM, which is “bulkier” than
CM, is due to their location at the interface between TM5 and
TM6. Of particular relevance is the protrusion of Cys-343 into
the central aqueous cavity, thereby rendering it susceptible to
labeling with the hydrophilic probe FM. Although residue Cys-
339 also displays some access to the central cavity, its close
proximity to TM1 provides a barrier to labeling with the “bulk-
iest” probe, FM. Residues Cys-331 and Cys-335 face the lipid
milieu and are, therefore, readily labeled by CM; however, only
the former is accessible to BM, and the time course for the
interaction is quite slow. Conceivably, residues proximal to
Cys-331 and Cys-335 provide a barrier to BM. Overall, the
topography of TM6 of the model is in good agreement with the
data presented in the current investigation, and the model was
subsequently used to infer the structural changes accompany-
ing nucleotide binding.
One of the initial events in the transport process is nucleo-
tide binding, but how important is this event to the overall drug
translocation mechanism? Evidence from investigations of
cross-link formation between helices surrounding the central
cavity (i.e. TMs 5, 6, 11, and 12) suggest that ATP binding does
not lead to significant structural change (28, 47). However,
structural information using either electron microscopy (21, 22)
or spectroscopy-based approaches (19, 20) indicates the con-
trary. These structural investigations are supported by a
wealth of functional information demonstrating a key role for
binding of nucleotide to instigate the translocation process (13,
18, 45, 48, 49). A drawback with the cross-linking studies
mentioned above is the necessity for large conformational
changes to enable detection and a reliance on the cross-link to
affect protein migration in SDS-PAGE. In addition, the studies
did not provide kinetic data on the interactions nor did they
involve full dose-response analyses, and together there is po-
tential to overlook more subtle conformational changes. In the
present investigation binding of the non-hydrolyzable ATP an-
alogue, AMP-PNP, produced a general loss in residue accessi-
bility that was most apparent for Cys-331 and Cys-339 and the
removal of Cys-343 from an aqueous accessible environment.
The possible structural changes to explain these changes in-
clude TM rotation, translational movement, or tilting. Fig. 5, b
and c, present proposed schematic models of P-gp TMDs that
best reflect the fluorescence labeling data described and pro-
ducing the most parsimonious alterations to TM6.
Although anti-clockwise rotation of TM6 would explain the
loss of Cys-339 and Cys-343 accessibility through their closer
approach to TM1, it does not explain the loss of Cys-331 label-
ing by BM and would suggest that Cys-333 movement away
from TM5 would render it susceptible to labeling. Conversely,
clockwise rotation of TM6 would account for the reduced Cys-
331 and Cys-343 labeling since the former would approach
TM1, and the latter moves closer to TM5. However, residue
Cys-339 would protrude directly into the central cavity and
thereby gain accessibility to FM, which it clearly does not.
Similarly, lateral movement of TM6 either to TM5 or to the
vicinity of TM1/TM4 can only explain a part of the data. In
contrast tilting or “straightening” of the longitudinal axis of
TM6 provides a more complete description. Tilting of TM6
would bring Cys-331 and Cys-335 closer to TM1 and account for
their low accessibility, whereas Cys-333, Cys-337, and Cys-341
remain packed against TM5. Residue Cys-339 is brought into
the proximity of TM1/TM4, hence its lower accessibility, and
Cys-343 assumes a configuration similar to Cys-339 in the
native state. Both the atomic model (30) and cross-linking data
(50) suggest that TM6 and TM12 are close to the cytoplasmic
leaflet of the bilayer, and it has been argued that this interac-
tion is used to “block” the aqueous cavity. Consequently, if TM6
were to tilt in response to ATP binding the effect would extend
the depth of the central cavity in P-gp, a finding that is sup-
ported by structural investigations (22).
The next stage of drug transport is driven by the hydrolysis
of nucleotide and data from EM, and spectroscopy-based inves-
tigations suggest that P-gp assumes a conformation that is
distinct from both the native and nucleotide-bound forms (19–
22). The present characterization of residue accessibility to
thiol-reactive probes concurs with a third distinct conforma-
tion. The major topographical changes in moving from the
AMP-PNP- to the ADP.Vi-bound state was accessibility of res-
idues Cys-333 and Cys-337 in addition to regaining Cys-339
labeling with BM. Cross-linking investigations with Tris-(2-
maleimidoethyl)amine suggest that TM6 rotates in an anti-
clockwise fashion (51). A more recent study by the same au-
thors provides an alternative conformational change in
response to ATP hydrolysis, namely that TM segments at the
extracellular face are brought closer together (47), analogous to
a tilting movement. Rotational changes only account for a part
of the current accessibility data; however, tilting of TM6 such
that the “extracellular” region is brought into the central cavity
provides a more complete reconciliation. Further tilting of TM6
would relieve the obstruction of Cys-339 to labeling caused by
TM1 in the nucleotide-bound state. Furthermore, Cys-331 and
Cys-335 would remain close to TM1 and, thus, inaccessible to
labeling. Residues Cys-333 and Cys-337 move away from TM5
and become labeled by BM and, since the former is furthest
from TM5, provides an explanation for its more rapid reaction
with the probe. Cys-341 remains close to TM5 and is only
labeled with CM, whereas Cys-343 remains localized as in the
AMP-PNP-bound state and, thus, inaccessible to FM.
The tilting of TM6 thereby provides a consistent explanation
for the data presented in the current investigation but also for
previous studies using cysteine-scanning mutagenesis and co-
valent cross-link formation. The EM data suggest that TM6 is
unlikely to be the only segment to undergo conformational
changes. Our data analysis predicts the tilting of TM6 relative
to those in proximity, but this does not rule out movement of
other helices. The helical tilting hypothesis also provides a
mechanism for interdomain communication during transport,
particularly given that TM6 is directly joined to the N-terminal
NBD. Finally, the nucleotide-driven tilting of TM6 is also com-
patible with the demonstrated alterations in drug binding site
affinity during ATP catalysis (13).
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